Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
海角七号
发表于 2024-8-8 15:32:39
166
0
0
Reporter Chen Xing
On August 7th, Novo Nordisk announced its H1 2024 results that the Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. Oral Smeaglutide (7mg and 14mg) was approved for marketing in the United States in September 2019, which is used as an auxiliary means of diet and exercise to help improve the blood sugar control of adult type 2 diabetes patients.
Rybelsus' breakthrough in weight loss indications will be an important development for oral GLP-1 preparations in the field of weight loss, and sales of semaglutide preparations are expected to further increase.
Successful Phase III study on oral administration of semaglutide for weight loss
The oral semaglutide Rybelsus (25mg), which has been approved as a hypoglycemic drug, has recently completed a phase III weight loss study.
On August 7th, Novo Nordisk announced its H1 2024 results that the Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. This study included 307 cases with a body mass index (BMI) ≥ 27kg/m& sup2; And accompanied by at least one weight related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI ≥ 30kg/m& sup2; The weight loss effect and safety of oral semaglutide (25mg, once daily) versus placebo were evaluated in overweight or obese adult subjects. The study lasted for 72 weeks, including a 1-week screening period, a 64 week treatment period, and a 7-week follow-up period.
The subjects in the oral semaglutide group received treatment in increasing doses over a period of 64 weeks, with a dose of 3mg taken from weeks 0-4, 7mg taken from weeks 5-8, 14mg taken from weeks 9-12, and 25mg taken from weeks 13-64. The primary endpoint of the study was the percentage change in body weight relative to baseline and the number of subjects who experienced a weight loss of at least 5% during the treatment period.
The baseline weight of the subjects was 105.9kg. The results showed that the weight loss of subjects in the oral semaglutide group was 13.6%, while the proportion in the placebo group was 2.2%. If all subjects persisted in completing the treatment, the weight loss in the oral semaglutide group was 16.6%, and the placebo group was 2.7%. In addition, oral semaglutide has shown good safety and tolerability in the study.
In September 2019, oral smeglutide (7mg and 14mg) was approved for marketing in the United States as an auxiliary means of diet and exercise to help improve the blood sugar control of adult type 2 diabetes patients. Meanwhile, the oral medication has been undergoing clinical research on weight loss indications.
In January this year, Novo Nordisk Megglutide Tablets (trade name: Novo Xin) was approved for marketing to treat type 2 diabetes, which is the first oral GLP-1 (glucagon like peptide-1) receptor agonist approved for marketing in China.
Terminate development of GLP-1/GIP dual receptor agonists once a month
According to the first half results released by Novo Nordisk, the sales of Ozempic, a hypoglycemic injection version of semaglutide, amounted to 56.685 billion Danish kroner, or 8.287 billion US dollars, a year-on-year increase of 36%; The sales revenue of Rybelsus, a hypoglycemic oral version of semaglutide, was 10.931 billion Danish kroner, equivalent to 1.598 billion US dollars, a year-on-year increase of 32%; The sales of the Simeglutide weight reducing version of Wegovy reached 21.036 billion Danish kroner, equivalent to 3.075 billion US dollars, a year-on-year increase of 74%.
The total sales revenue of the three products of Simeglutide is about 12.95 billion US dollars, further narrowing the gap with the global "King of Medicine" K drug's sales revenue of 14.217 billion US dollars. Rybelsus' breakthrough in weight loss indications will also be an important breakthrough for oral GLP-1 preparations in the field of weight loss, and sales are expected to further increase.
At the same time as announcing the results of Rybelsus' Phase III weight loss study, Novo Nordisk also disclosed that due to product portfolio considerations, Novo Nordisk has terminated the Phase I development of once monthly subcutaneous injection of GLP-1/GIP dual receptor agonists. In the layout of GLP-1/GIP, Novo Nordisk is still pushing forward with a weekly pipeline.
Tilpotide, a subsidiary of Eli Lilly, is currently the world's first and only approved glucose dependent insulinotropic polypeptide (GIP)/glucagon like peptide-1 (GLP-1) receptor agonist. In May 2022, Mounjaro, a hypoglycemic version of tilboptide, was approved for marketing in the United States; In November 2023, the weight loss version of Zepbound, also obtained approval from the US Food and Drug Administration (FDA) for marketing.
In July of this year, the indication for long-term weight management of Tilpotide Injection was approved by the National Medical Products Administration (NMPA). This is the second GLP-1 weight loss drug approved in China after Novo Nordisk Smiaglutide. At present, Tilpotide is also considered the biggest competitor of semaglutide.
In addition, Novo Nordisk has also halted the ongoing Phase I trials of VAP-1 inhibitors after the completion of the first part of the study evaluating their safety, tolerability, pharmacokinetics, and pharmacodynamics. Due to product portfolio considerations, the trial has been discontinued, and further development of VAP-1 inhibitors in metabolic associated steatohepatitis (MASH) has also been terminated.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Novo Nordisk's US stock fell more than 5% before trading
- Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024
- Lilly weight loss pills are crazily chasing after semaglutide
- Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
- Novo Nordisk faces US Senate inquiry over weight loss drug prices
- The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏
-
10月1日、極クリプトン自動車が発表したデータによると、今年第3四半期に新車が累計14万2900台納入され、前年同期比81%増となった。このうち、9月に新車を納入したのは2万13万人で、前年同期比77%、前月比18%増だっ ...
- 内托体头
- 5 小时前
- 支持
- 反对
- 回复
- 收藏